[HTML][HTML] Transcriptome-Wide Analysis of RNA N6-Methyladenosine Modification in Adriamycin-Resistant Acute Myeloid Leukemia Cells
S Fang, B Peng, Y Wen, J Yang, H Wang… - Frontiers in …, 2022 - frontiersin.org
Acute myeloid leukemia (AML) is one of the most aggressive hematopoietic malignancies.
Patients still suffer from refractory/relapsed disease after anthracycline-based therapy, which …
Patients still suffer from refractory/relapsed disease after anthracycline-based therapy, which …
Transcriptome-Wide Analysis of RNA N6-Methyladenosine Modification in Adriamycin-Resistant Acute Myeloid Leukemia Cells.
S Fang, B Peng, Y Wen, J Yang, H Wang… - Frontiers in …, 2022 - europepmc.org
Acute myeloid leukemia (AML) is one of the most aggressive hematopoietic malignancies.
Patients still suffer from refractory/relapsed disease after anthracycline-based therapy, which …
Patients still suffer from refractory/relapsed disease after anthracycline-based therapy, which …
[HTML][HTML] Transcriptome-Wide Analysis of RNA N6-Methyladenosine Modification in Adriamycin-Resistant Acute Myeloid Leukemia Cells
S Fang, B Peng, Y Wen, J Yang, H Wang… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is one of the most aggressive hematopoietic malignancies.
Patients still suffer from refractory/relapsed disease after anthracycline-based therapy, which …
Patients still suffer from refractory/relapsed disease after anthracycline-based therapy, which …
Transcriptome-Wide Analysis of RNA N6-Methyladenosine Modification in Adriamycin-Resistant Acute Myeloid Leukemia Cells
S Fang, B Peng, Y Wen, J Yang… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is one of the most aggressive hematopoietic malignancies.
Patients still suffer from refractory/relapsed disease after anthracycline-based therapy, which …
Patients still suffer from refractory/relapsed disease after anthracycline-based therapy, which …